共 50 条
Ubiquitin receptors play redundant roles in the proteasomal degradation of the p53 repressor MDM2
被引:0
作者:
Sparks, Alison
[1
]
Kelly, Christopher J.
[1
,2
]
Saville, Mark K.
[1
,3
]
机构:
[1] Univ Dundee, Sch Med, Dundee, Scotland
[2] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[3] Silver River Editing, Dundee, Scotland
基金:
欧洲研究理事会;
英国惠康基金;
关键词:
ADRM1;
PSMD16;
hRpn13;
MDM2;
p53;
TP53;
proteasomal ubiquitin receptor;
redundancy;
S5A;
PSMD4;
hRpn10;
MULTIUBIQUITIN-CHAIN-BINDING;
26 S PROTEASOME;
POLYUBIQUITIN CHAINS;
PROTEIN-DEGRADATION;
CANCER DEPENDENCIES;
LARGE-SCALE;
VWA DOMAIN;
RPN10;
SUBUNIT;
PROMOTES;
D O I:
10.1002/1873-3468.14436
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Much remains to be determined about the participation of ubiquitin receptors in proteasomal degradation and their potential as therapeutic targets. Suppression of the ubiquitin receptor S5A/PSMD4/hRpn10 alone stabilises p53/TP53 but not the key p53 repressor MDM2. Here, we observed S5A and the ubiquitin receptors ADRM1/PSMD16/hRpn13 and RAD23A and B functionally overlap in MDM2 degradation. We provide further evidence that degradation of only a subset of ubiquitinated proteins is sensitive to S5A knockdown because ubiquitin receptor redundancy is commonplace. p53 can be upregulated by S5A modulation while degradation of substrates with redundant receptors is maintained. Our observations and analysis of Cancer Dependency Map (DepMap) screens show S5A depletion/loss substantially reduces cancer cell line viability. This and selective S5A dependency of proteasomal substrates make S5A a target of interest for cancer therapy.
引用
收藏
页码:2746 / 2767
页数:22
相关论文
共 50 条